US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 01:33:49 Source:styleViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Eleanor Tomlinson puts on a leggy display in sparkly black minidress as she joins co
Next:Joe Rogan's 'brain
You may also like
- Uber and Lyft say they'll stay in Minnesota after Legislature passes driver pay compromise
- 2022 China New Media Conference Kicks off in Changsha
- Village in China's Henan Transformed by Cultural Industries
- Martial Arts Enthusiasts Found Training Class for Local Children
- Jude Bellingham's new model girlfriend Laura Celia Valk looks sensational in a figure
- China to Further Improve Services for Village Residents
- GLOBALink
- Guizhou Achieves Progress in Economic Development, Poverty Alleviation
- Mohammad Mokhber: Who is Iran’s acting president?